VVD-214

Key Product Details

Product Description

VVD-214 is a potent werner syndrome helicase (WRN) covalent allosteric inhibitor (IC₅₀ = 0.13 μM and 2.4 μM with and without ATP, respectively). The selective binding of VVD-214 to cysteine C727 of WRN triggers double-stranded DNA breaks, nuclear swellings, cell death and tumor regression in microsatellite instability-high (MSI-H) colorectal cancer models. Highly stable in hepatocytes and whole blood, VVD-214 is orally bioavailable.

Licensing Information

Sold with permission from Vividion Therapeutics

Product Specifications for VVD-214

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for VVD-214

The following data is based on the product molecular weight 437.46.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	4.57 mL	22.86 mL	45.72 mL
2.5 mM	0.91 mL	4.57 mL	9.14 mL
5 mM	0.46 mL	2.29 mL	4.57 mL
25 mM	0.09 mL	0.46 mL	0.91 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Baltgalvis Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase. Nature 2024 PMID: 38658751
• Kikuchi Identification of VVD-214/RO7589831, a clinical-stage, covalent allosteric inhibitor of WRN helicase for the treatment of MSI-high cancers. J.Med.Chem. 2025 PMID: 40964743

Product Documents for VVD-214